用于治疗系统性硬化症相关肺动脉高压的内皮素-1受体拮抗剂 - Suppr

Suppr

超能文献

Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.

作者信息

Varga John

出版信息

Curr Rheumatol Rep. 2003 Apr;5(2):145-6. doi: 10.1007/s11926-003-0042-4.

DOI:10.1007/s11926-003-0042-4

PMID:12628045

Abstract

摘要

相似文献

Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.

Curr Rheumatol Rep. 2003 Apr;5(2):145-6. doi: 10.1007/s11926-003-0042-4.

[Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].

Z Rheumatol. 2004 Dec;63(6):495-7. doi: 10.1007/s00393-004-0594-3.

[Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].

Med Monatsschr Pharm. 2006 Jul;29(7):242-5.

Resolution of severe digital ulceration during a course of Bosentan therapy.

Ann Intern Med. 2005 May 3;142(9):802-3. doi: 10.7326/0003-4819-142-9-200505030-00029.

[Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].

Harefuah. 2008 Apr;147(4):287-9, 376.

Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

Inflamm Allergy Drug Targets. 2011 Feb;10(1):19-26. doi: 10.2174/187152811794352088.

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Lancet. 2001 Oct 6;358(9288):1119-23. doi: 10.1016/S0140-6736(01)06250-X.

Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.

J Dermatol Sci. 2009 Jul;55(1):66-7. doi: 10.1016/j.jdermsci.2009.02.013. Epub 2009 Apr 1.

[Blockade of endothelin receptor with bosentan--a new principle of treatment in pulmonary arterial hypertension].

Ugeskr Laeger. 2003 Jul 14;165(29):2891-4.

Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.

Australas J Dermatol. 2012 May;53(2):e32-3. doi: 10.1111/j.1440-0960.2010.00719.x. Epub 2010 Nov 29.

引用本文的文献

MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors.

Biomedicines. 2022 Mar 8;10(3):629. doi: 10.3390/biomedicines10030629.

本文引用的文献

Bosentan therapy for pulmonary arterial hypertension.

N Engl J Med. 2002 Mar 21;346(12):896-903. doi: 10.1056/NEJMoa012212.

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Lancet. 2001 Oct 6;358(9288):1119-23. doi: 10.1016/S0140-6736(01)06250-X.

Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients.

Br J Rheumatol. 1996 Oct;35(10):989-93. doi: 10.1093/rheumatology/35.10.989.

Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone.

Arthritis Rheum. 1995 Jan;38(1):1-4. doi: 10.1002/art.1780380102.

Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis.

Am J Med. 1983 Jul;75(1):65-74. doi: 10.1016/0002-9343(83)91169-5.

Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

Arthritis Rheum. 1986 Apr;29(4):515-24. doi: 10.1002/art.1780290409.

Isolated diffusing capacity reduction in systemic sclerosis.

Arthritis Rheum. 1992 Jul;35(7):765-70. doi: 10.1002/art.1780350709.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验